Punicalagin alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via NRF2/HO-1 pathway
Regenerative Therapy · 2026-12 · 33 · 101164
DOI: 10.1016/j.reth.2026.101164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Regenerative Therapy, 2026-12. Verfasst von Yijun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The senescence and abnormal osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) are important causes of senile osteoporosis. Punicalagin (PUN), a natural polyphenol extracted from pomegranate peel, has demonstrated antioxidant activity in preclinical studies. This study aims to investigate the inhibitory effect of PUN on the aging of BMSCs and its therapeutic effect on senile osteoporosis.
Methods
The senescence of BMSCs were induced by hydrogen peroxide (H2O2) to assess the therapeutic effect of PUN. Intracellular reactive oxygen species measurements, the senescence β-galactosidase staining, western blotting, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) were conducted to evaluate the senescence of BMSCs. Alkaline phosphatase staining, Alizarin red S staining, western blotting, and RT-qPCR were performed to assess the osteogenic differentiation of senescent BMSCs. Transcriptome sequencing was conducted to explore the underlying mechanism. In vivo, the therapeutic effects of PUN were investigated in aging rats with senile osteoporosis.
Results
PUN reversed the senescence of BMSCs and promoted the osteogenic differentiation in a dose-dependent manner. Mechanistically, PUN activated the nuclear factor erythroid 2-related factor 2 (NRF2)/heme oxygenase-1 (HO-1) pathway to protect BMSCs from oxidative stress. In aging rats with senile osteoporosis, intraperitoneal injection of PUN can promote osteogenesis and reduce aging-related bone loss in vivo.
Conclusion
PUN alleviates senile osteoporosis by inhibiting the senescence of BMSCs via NRF2/HO-1 pathway, representing a candidate therapeutic drug for aging-related bone diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215006, China.
- Department of Orthopedics, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi, 214000, China.
- Department of Orthopedics, Hai'an People's Hospital, Hai'an, 226000, China.
- Department of Orthopedics, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, 215200, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Qin, Y., Wang, T., Zhang, W., Chen, K., Geng, D., Yan, Z., Xu, Y., & Lv, S. (2026). Punicalagin alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via NRF2/HO-1 pathway. Regenerative Therapy, 33, 101164. https://doi.org/10.1016/j.reth.2026.101164
Vancouver
Wang Y, Qin Y, Wang T, Zhang W, Chen K, Geng D, et al. Punicalagin alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via NRF2/HO-1 pathway. Regenerative Therapy. 2026;33:101164. doi:10.1016/j.reth.2026.101164
BibTeX
@article{Wang2026,
author = {Wang, Yijun and Qin, Yi and Wang, Tianhao and Zhang, Wenhao and Chen, Kai and Geng, Dechun and Yan, Zhanjun and Xu, Yaozeng and Lv, Shujun},
title = {Punicalagin alleviates senile osteoporosis by inhibiting the senescence of bone mesenchymal stem cells via NRF2/HO-1 pathway},
journal = {Regenerative Therapy},
year = {2026},
volume = {33},
pages = {101164},
doi = {10.1016/j.reth.2026.101164}
}
EUVIMED